E. Ohman J or Asset Management AB Invests $3.50 Million in Pfizer Inc. $PFE

E. Ohman J or Asset Management AB bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 140,617 shares of the biopharmaceutical company’s stock, valued at approximately $3,501,000.

Other large investors also recently made changes to their positions in the company. Avanza Fonder AB boosted its holdings in Pfizer by 1.3% during the fourth quarter. Avanza Fonder AB now owns 585,928 shares of the biopharmaceutical company’s stock worth $14,590,000 after purchasing an additional 7,290 shares during the last quarter. First Heartland Consultants Inc. increased its stake in Pfizer by 6.4% in the 4th quarter. First Heartland Consultants Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 781 shares during the last quarter. Capital Asset Advisory Services LLC lifted its position in shares of Pfizer by 1.4% during the 4th quarter. Capital Asset Advisory Services LLC now owns 110,950 shares of the biopharmaceutical company’s stock worth $2,821,000 after buying an additional 1,520 shares in the last quarter. Cultivar Capital Inc. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $209,000. Finally, Community Trust & Investment Co. grew its holdings in shares of Pfizer by 1.4% in the fourth quarter. Community Trust & Investment Co. now owns 114,034 shares of the biopharmaceutical company’s stock valued at $2,839,000 after acquiring an additional 1,623 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.7%

Shares of PFE opened at $26.77 on Tuesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The stock has a market cap of $152.23 billion, a PE ratio of 19.68 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $26.71 and its 200-day moving average price is $25.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $0.63 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PFE shares. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. TD Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Morgan Stanley set a $27.00 target price on Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.14.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 topline shows robust efficacy (~73% in pre-specified analyses), signaling clear commercial potential if regulators accept the data and approve the shot. BusinessWire: Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
• Positive Sentiment: Pfizer’s defensive income profile (high dividend yield cited in market coverage) and recent YTD recovery are attracting dividend‑focused investors, providing demand support amid market volatility. MarketBeat: 5 High-Yield Stocks to Shield Your Portfolio From the Storm
• Positive Sentiment: Technical/market narrative: coverage notes Pfizer is showing signs of outperformance versus prior years, which can attract momentum and rotation flows into the name. Fool: Pfizer Stock Is Doing Something It Hasn’t Done Since 2022
• Neutral Sentiment: Pfizer says it will pursue regulatory submissions despite the trial missing its formal primary endpoint — this keeps an approval path alive but raises review uncertainty and timing questions. CNBC: Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
• Negative Sentiment: The trial failed to meet its primary endpoint due to a low number of infection events, making the results statistically inconclusive and injecting regulatory and commercial risk; partner Valneva’s stock plunged on the news, reflecting investor concern about approval odds and program economics. WSJ: Pfizer’s Lyme Vaccine Shows Strong Efficacy but Misses Mark in Study

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.